[Skip to Navigation]
Article
February 1996

Cerebrospinal Fluid Concentrations of Soluble Amyloid β-Protein and Apolipoprotein E in Patients With Alzheimer's Disease: Correlations With Amyloid Load in the Brain

Author Affiliations

From the Departments of Immunology (Drs Pirttilä and Mehta), Virology (Dr Kim), and Pathological Neurobiology (Dr Wisniewski), Institue for Basic Research in Developmental Disabilities, Staten Island, NY; and Department of Neurology, Kuopio University Hospital and University of Kuopio (Finland) (Drs Soininen, Heinonen, Paljärvi, Kosunen, and Riekkinen).

Arch Neurol. 1996;53(2):189-193. doi:10.1001/archneur.1996.00550020105022
Abstract

Objective:  To compare soluble amyloid β-protein and apolipoprotein E levels in cerebrospinal fluid (CSF) and brain extracts from patients with definite Alzheimer's disease.

Setting:  University medical center.

Patients:  Nineteen patients with definite Alzheimer's disease.

Main Outcome Measures:  Soluble amyloid β-protein and apolipoprotein E levels in CSF, in neutral and low-pH brain extracts, and in formic acid—treated sections of the frontal, temporal, and cerebellar cortices, measured using enzyme-linked immunosorbent assay.

Results:  Soluble amyloid β-protein and apolipoprotein E levels in CSF were significantly lower in patients with congophilic angiopathy than in those without angiopathy. The levels did not correlate with the number of amyloid plaques in the neocortex. There was, however, a tendency toward an inverse correlation between the amount of amyloid β-protein in the frontal cortex extracts and the soluble amyloid β-protein level in CSF.

Conclusion:  Soluble amyloid β-protein levels in CSF may reflect amyloid accumulation in brain blood vessels.

Add or change institution
×